Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97


First-in-human Phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.

Wen PY, Cloughesy TF, Olivero AG, Morrissey KM, Wilson TR, Lu X, Mueller LU, Coimbra AF, Ellingson BM, Gerstner E, Lee EQ, Rodon J.

Clin Cancer Res. 2020 Jan 14. pii: clincanres.2808.2019. doi: 10.1158/1078-0432.CCR-19-2808. [Epub ahead of print]


Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators.

Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30690-4. doi: 10.1016/S1470-2045(19)30690-4. [Epub ahead of print]


Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators.

Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30691-6. doi: 10.1016/S1470-2045(19)30691-6. [Epub ahead of print]


Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.

Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, Jhaveri K, Chandarlapaty S, Rabadan R, Reznik E, Smith ML, Sebra R, Schimmoller F, Wilson TR, Friedman LS, Cantley LC, Scaltriti M, Baselga J.

Science. 2019 Nov 8;366(6466):714-723. doi: 10.1126/science.aaw9032.


Observing the 3D Chemical Bond and its Energy Distribution in a Projected Space.

Wilson TR, Rajivmoorthy M, Goss J, Riddle S, Eberhart ME.

Chemphyschem. 2019 Dec 16;20(24):3289-3305. doi: 10.1002/cphc.201900962. Epub 2019 Dec 4.


Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.

Moore HM, Savage HM, O'Brien C, Zhou W, Sokol ES, Goldberg ME, Metcalfe C, Friedman LS, Lackner MR, Wilson TR.

Mol Cancer Ther. 2020 Jan;19(1):292-303. doi: 10.1158/1535-7163.MCT-19-0284. Epub 2019 Sep 18.


Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E.

Lancet Oncol. 2019 Sep;20(9):1226-1238. doi: 10.1016/S1470-2045(19)30334-1. Epub 2019 Aug 8.


A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.

Abramson VG, Oliveira M, Cervantes A, Wildiers H, Patel MR, Bauer TM, Bedard PL, Becerra C, Richey S, Wei MC, Reyner E, Bond J, Cui N, Wilson TR, Moore HM, Saura C, Krop IE.

Breast Cancer Res Treat. 2019 Nov;178(1):121-133. doi: 10.1007/s10549-019-05360-3. Epub 2019 Jul 31.


Malnutrition, nutritional interventions and clinical outcomes of patients with acute small bowel obstruction: results from a national, multicentre, prospective audit.

Lee MJ, Sayers AE, Drake TM, Singh P, Bradburn M, Wilson TR, Murugananthan A, Walsh CJ, Fearnhead NS; NASBO Steering Group and NASBO Collaborators.

BMJ Open. 2019 Jul 27;9(7):e029235. doi: 10.1136/bmjopen-2019-029235.


Charge Density in Enzyme Active Site as a Descriptor of Electrostatic Preorganization.

Fuller J 3rd, Wilson TR, Eberhart ME, Alexandrova AN.

J Chem Inf Model. 2019 May 28;59(5):2367-2373. doi: 10.1021/acs.jcim.8b00958. Epub 2019 Mar 5.


Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers.

Wilson TR, Udyavar AR, Chang CW, Spoerke JM, Aimi J, Savage HM, Daemen A, O'Shaughnessy JA, Bourgon R, Lackner MR.

Mol Cancer Res. 2019 Jan;17(1):97-108. doi: 10.1158/1541-7786.MCR-18-0619. Epub 2018 Aug 31.


Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J.

Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. Epub 2018 May 23.


Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.

Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C.

J Natl Cancer Inst. 2019 Jan 1;111(1):69-77. doi: 10.1093/jnci/djy076.


Effect of stall design on dairy calf transition to voluntary feeding on an automatic milk feeder after introduction to group housing.

Wilson TR, LeBlanc SJ, DeVries TJ, Haley DB.

J Dairy Sci. 2018 Jun;101(6):5307-5316. doi: 10.3168/jds.2017-14011. Epub 2018 Mar 15.


Current management of small bowel obstruction in the UK: results from the National Audit of Small Bowel Obstruction clinical practice survey.

Lee MJ, Sayers AE, Wilson TR, Acheson AG, Anderson ID, Fearnhead NS; NASBO Steering Group.

Colorectal Dis. 2018 Jul;20(7):623-630. doi: 10.1111/codi.14016.


UK-based, multisite, prospective cohort study of small bowel obstruction in acute surgical services: National Audit of Small Bowel Obstruction (NASBO) protocol.

Lee MJ, Sayers AE, Drake TM, Hollyman M, Bradburn M, Hind D, Wilson TR, Fearnhead NS; NASBO Steering Group.

BMJ Open. 2017 Oct 5;7(10):e016796. doi: 10.1136/bmjopen-2017-016796.


The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.

Wilson TR, Yu J, Lu X, Spoerke JM, Xiao Y, O'Brien C, Savage HM, Huw LY, Zou W, Koeppen H, Forrest WF, Fridlyand J, Fu L, Tam R, Schleifman EB, Sumiyoshi T, Molinero L, Hampton GM, O'Shaughnessy JA, Lackner MR.

NPJ Breast Cancer. 2016 Jul 13;2:16022. doi: 10.1038/npjbcancer.2016.22. eCollection 2016.


Predicting Chemical Reactivity from the Charge Density through Gradient Bundle Analysis: Moving beyond Fukui Functions.

Morgenstern A, Wilson TR, Eberhart ME.

J Phys Chem A. 2017 Jun 8;121(22):4341-4351. doi: 10.1021/acs.jpca.7b00630. Epub 2017 May 30.


Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.

Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez SM, Savage HM, Sampath D, Salphati L, Lin RS, Jin H, Parmar H, Hsu JY, Von Hoff DD, Baselga J.

Cancer Discov. 2017 Jul;7(7):704-715. doi: 10.1158/2159-8290.CD-16-1080. Epub 2017 Mar 22. Erratum in: Cancer Discov. 2018 Nov;8(11):1491.


Readmissions after general surgery: a prospective multicenter audit.

Lee MJ, Daniels SL, Wild JRL, Wilson TR; SYSuRG RAGeS Group.

J Surg Res. 2017 Mar;209:53-59. doi: 10.1016/j.jss.2016.09.020. Epub 2016 Sep 19.


Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.

Fumagalli D, Wilson TR, Salgado R, Lu X, Yu J, O'Brien C, Walter K, Huw LY, Criscitiello C, Laios I, Jose V, Brown DN, Rothé F, Maetens M, Zardavas D, Savas P, Larsimont D, Piccart-Gebhart MJ, Michiels S, Lackner MR, Sotiriou C, Loi S.

Ann Oncol. 2016 Oct;27(10):1860-6. doi: 10.1093/annonc/mdw286.


The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase.

Hoeflich KP, Guan J, Edgar KA, O'Brien C, Savage H, Wilson TR, Neve RM, Friedman LS, Wallin JJ.

Genes Cancer. 2016 Mar;7(3-4):73-85. doi: 10.18632/genesandcancer.100.


Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.

Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, Aimi J, Derynck MK, Chen M, Chan IT, Amler LC, Hampton GM, Johnston S, Krop I, Schmid P, Lackner MR.

Nat Commun. 2016 May 13;7:11579. doi: 10.1038/ncomms11579.


Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.

Schmid P, Pinder SE, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Bundred N, Hadad S, Shia A, Sarker SJ, Lim L, Gazinska P, Woodman N, Korbie D, Trau M, Mainwaring P, Gendreau S, Lackner MR, Derynck M, Wilson TR, Butler H, Earl G, Parker P, Purushotham A, Thompson A.

J Clin Oncol. 2016 Jun 10;34(17):1987-94. doi: 10.1200/JCO.2015.63.9179. Epub 2016 Mar 14.


Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer.

Diéras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, Koeppen H, Wilson TR, Xiao Y, Shames DS, Mocci S, Chen M, Schmid P.

Ann Oncol. 2015 Sep;26(9):1904-10. doi: 10.1093/annonc/mdv263. Epub 2015 Jul 22.


Utility of contrast enema to assess anastomotic integrity and the natural history of radiological leaks after low rectal surgery: systematic review and meta-analysis.

Habib K, Gupta A, White D, Mazari FA, Wilson TR.

Int J Colorectal Dis. 2015 Aug;30(8):1007-14. doi: 10.1007/s00384-015-2225-7. Epub 2015 Apr 29. Review.


Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.

Wilson TR, Xiao Y, Spoerke JM, Fridlyand J, Koeppen H, Fuentes E, Huw LY, Abbas I, Gower A, Schleifman EB, Desai R, Fu L, Sumiyoshi T, O'Shaughnessy JA, Hampton GM, Lackner MR.

Breast Cancer Res Treat. 2014 Nov;148(2):315-25. doi: 10.1007/s10549-014-3163-8. Epub 2014 Oct 22.


The morbidity of negative appendicectomy.

Lee M, Paavana T, Mazari F, Wilson TR.

Ann R Coll Surg Engl. 2014 Oct;96(7):517-20. doi: 10.1308/003588414X13946184903801.


Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.

Arthur LM, Turnbull AK, Renshaw L, Keys J, Thomas JS, Wilson TR, Lackner MR, Sims AH, Dixon JM.

Breast Cancer Res Treat. 2014 Aug;147(1):211-9. doi: 10.1007/s10549-014-3080-x. Epub 2014 Aug 9.


Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition.

Edgar KA, Crocker L, Cheng E, Wagle MC, Wongchenko M, Yan Y, Wilson TR, Dompe N, Neve RM, Belvin M, Sampath D, Friedman LS, Wallin JJ.

Genes Cancer. 2014 Mar;5(3-4):113-26.


The success of rectus and gracilis muscle flaps in the treatment of chronic pelvic sepsis and persistent perineal sinus: a systematic review.

Wilson TR, Welbourn H, Stanley P, Hartley JE.

Colorectal Dis. 2014 Oct;16(10):751-9. doi: 10.1111/codi.12663. Review.


The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation.

Raha D, Wilson TR, Peng J, Peterson D, Yue P, Evangelista M, Wilson C, Merchant M, Settleman J.

Cancer Res. 2014 Jul 1;74(13):3579-90. doi: 10.1158/0008-5472.CAN-13-3456. Epub 2014 May 8.


Obesity is associated with higher 4E-BP1 expression in endometrial cancer.

Libby EF, Azrad M, Novak L, Vazquez AI, Wilson TR, Demark-Wahnefried W.

Curr Biomark Find. 2014 Jan 15;2014(4):1-7.


Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers.

Schleifman EB, Desai R, Spoerke JM, Xiao Y, Wong C, Abbas I, O'Brien C, Patel R, Sumiyoshi T, Fu L, Tam RN, Koeppen H, Wilson TR, Raja R, Hampton GM, Lackner MR.

PLoS One. 2014 Feb 10;9(2):e88401. doi: 10.1371/journal.pone.0088401. eCollection 2014.


Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer.

Huw LY, O'Brien C, Pandita A, Mohan S, Spoerke JM, Lu S, Wang Y, Hampton GM, Wilson TR, Lackner MR.

Oncogenesis. 2013 Dec 23;2:e83. doi: 10.1038/oncsis.2013.46.


Influence of enhanced recovery after surgery pathways and laparoscopic surgery on health-related quality of life.

Khan SA, Ullah S, Ahmed J, Wilson TR, McNaught C, Hartley J, Macfie J.

Colorectal Dis. 2013 Jul;15(7):900-7. doi: 10.1111/codi.12191.


High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck.

Shames DS, Carbon J, Walter K, Jubb AM, Kozlowski C, Januario T, Do A, Fu L, Xiao Y, Raja R, Jiang B, Malekafzali A, Stern H, Settleman J, Wilson TR, Hampton GM, Yauch RL, Pirzkall A, Amler LC.

PLoS One. 2013;8(2):e56765. doi: 10.1371/journal.pone.0056765. Epub 2013 Feb 28. Erratum in: PLoS One. 2013;8(6). doi:10.1371/annotation/63f57c72-c869-4ef5-94d1-3cbd6c2e3678. AnDo [corrected to Do, An].


Pitfalls in the interpretation of standardised quality of life instruments for individual patients? A qualitative study in colorectal cancer.

Wilson TR, Birks Y, Alexander DJ.

Qual Life Res. 2013 Sep;22(7):1879-88. doi: 10.1007/s11136-012-0303-7. Epub 2012 Nov 8.


Raised intraocular pressure (IOP) and perioperative visual loss in laparoscopic colorectal surgery: a catastrophe waiting to happen? A systematic review of evidence from other surgical specialities.

Pinkney TD, King AJ, Walter C, Wilson TR, Maxwell-Armstrong C, Acheson AG.

Tech Coloproctol. 2012 Oct;16(5):331-5. doi: 10.1007/s10151-012-0879-5. Epub 2012 Aug 31. Review.


Mechanisms of acquired resistance to targeted cancer therapies.

Lackner MR, Wilson TR, Settleman J.

Future Oncol. 2012 Aug;8(8):999-1014. doi: 10.2217/fon.12.86. Review.


Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J.

Nature. 2012 Jul 26;487(7408):505-9. doi: 10.1038/nature11249.


EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling.

Wilson KJ, Mill C, Lambert S, Buchman J, Wilson TR, Hernandez-Gordillo V, Gallo RM, Ades LM, Settleman J, Riese DJ 2nd.

Growth Factors. 2012 Apr;30(2):107-16. doi: 10.3109/08977194.2011.649918. Epub 2012 Jan 20. Review.


Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.

Wilson TR, Lee DY, Berry L, Shames DS, Settleman J.

Cancer Cell. 2011 Aug 16;20(2):158-72. doi: 10.1016/j.ccr.2011.07.011.


In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide.

Logan AE, Wilson TR, Fenning C, Cummins R, Kay E, Johnston PG, Longley DB.

Apoptosis. 2010 Dec;15(12):1435-43. doi: 10.1007/s10495-010-0533-5.


Could pre-mortem computerised tomography scans reduce the need for coroner's post-mortem examinations?

Owais AE, Wilson TR, Khan SA, Jaidev J, Renwick I, Mitchell C, Macfie J.

Ann R Coll Surg Engl. 2010 Jul;92(5):422-4. doi: 10.1308/003588410X12628812460137. Epub 2010 Apr 9.


Inflammatory fibroid polyp (Vanek's tumour), an unusual large polyp of the jejunum: a case report.

Rehman S, Gamie Z, Wilson TR, Coup A, Kaur G.

Cases J. 2009 May 18;2:7152. doi: 10.1186/1757-1626-2-7152.


Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing.

Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O'Byrne K, Le-Clorrenec C, Holohan C, Fennell DA, Johnston PG, Longley DB.

Cell Death Differ. 2009 Oct;16(10):1352-61. doi: 10.1038/cdd.2009.76. Epub 2009 Jun 19.


Anti-apoptotic mechanisms of drug resistance in cancer.

Wilson TR, Johnston PG, Longley DB.

Curr Cancer Drug Targets. 2009 May;9(3):307-19. Review.


A qualitative study of patient perspectives of health-related quality of life in colorectal cancer: comparison with disease-specific evaluation tools.

Wilson TR, Birks YF, Alexander DJ.

Colorectal Dis. 2010 Aug;12(8):762-9. doi: 10.1111/j.1463-1318.2009.01857.x. Epub 2009 Apr 2.


Clinical and non-clinical factors influencing postoperative health-related quality of life in patients with colorectal cancer.

Wilson TR, Alexander DJ.

Br J Surg. 2008 Nov;95(11):1408-15. doi: 10.1002/bjs.6376.


Supplemental Content

Loading ...
Support Center